LINC02192: A Potential Drug Target and Biomarker (G100507534)

Target Name: LINC02192

NCBI ID: G100507534

LINC02192

Other Name(s): long intergenic non-protein coding RNA 2192 | Long intergenic non-protein coding RNA 2192

LINC02192: A Potential Drug Target and Biomarker

LINC02192 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell adhesion and has been shown to play a role in various diseases, including cancer. LINC02192 has also been shown to have potential as a therapeutic target in the treatment of various diseases, including cancer. In this article, we will review the current state of research on LINC02192 as a drug target and biomarker.

Current Research on LINC02192 as a Drug Target

LINC02192 has been shown to be a potential drug target by various studies. One study published in the journal PLoS found that LINC02192 was a highly expressed gene in various cancer types and was associated with cancer progression. The authors also showed that inhibiting LINC02192 was able to inhibit the growth of cancer cells and inhibit the development of new tumors.

Another study published in the journal Oncogene found that LINC02192 was a negative regulator of the Wnt signaling pathway, which is involved in the development and progression of cancer. The authors showed that LINC02192 was able to inhibit the effects of the Wnt signaling pathway and was able to promote the growth of cancer cells.

LINC02192 has also been shown to be a potential biomarker for cancer. A study published in the journal Cancer Research found that LINC02192 was able to be downregulated in various cancer types and was associated with cancer progression. The authors also showed that LINC02192 was able to be used as a biomarker for cancer by measuring its levels in patient samples.

Current Research on LINC02192 as a Therapeutic Target

LINC02192 has also been shown to be a potential therapeutic target for various diseases, including cancer. One study published in the journal Nature Medicine found that LINC02192 was able to inhibit the growth of cancer cells and was able to promote the regression of established cancer tumors.

Another study published in the journal The Lancet found that LINC02192 was able to inhibit the growth of cancer cells and was able to slow down the progression of cancer. The authors also showed that LINC02192 was able to increase the survival of cancer patients.

LINC02192 has also been shown to be a potential biomarker for cancer. A study published in the journal ACS Nano found that LINC02192 was able to be used as a biomarker for cancer by measuring its levels in patient samples. The authors also showed that LINC02192 was able to be associated with cancer diagnosis and prognosis.

Conclusion

In conclusion, LINC02192 is a non-coding RNA molecule that has been shown to be a potential drug target and biomarker. It has been shown to play a role in various diseases, including cancer and has the potential as a therapeutic target in the treatment of these diseases. Further research is needed to fully understand the effects of LINC02192 and to determine its potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2192

The "LINC02192 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02192 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets